- Home
- DFH vs HRMY Comparison
DFH vs HRMY Comparison
Compare DFH & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFH
- HRMY
- Stock Information
- Founded
- DFH 2008
- HRMY 2017
- Country
- DFH United States
- HRMY United States
- Employees
- DFH N/A
- HRMY N/A
- Industry
- DFH Homebuilding
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- DFH Consumer Discretionary
- HRMY Health Care
- Exchange
- DFH Nasdaq
- HRMY Nasdaq
- Market Cap
- DFH 2.1B
- HRMY 2.0B
- IPO Year
- DFH 2021
- HRMY 2020
- Fundamental
- Price
- DFH $22.39
- HRMY $31.89
- Analyst Decision
- DFH Hold
- HRMY Strong Buy
- Analyst Count
- DFH 1
- HRMY 9
- Target Price
- DFH $28.00
- HRMY $54.22
- AVG Volume (30 Days)
- DFH 469.6K
- HRMY 611.9K
- Earning Date
- DFH 07-31-2025
- HRMY 08-05-2025
- Dividend Yield
- DFH N/A
- HRMY N/A
- EPS Growth
- DFH 14.93
- HRMY 13.13
- EPS
- DFH 3.34
- HRMY 2.62
- Revenue
- DFH $4,613,677,000.00
- HRMY $744,852,000.00
- Revenue This Year
- DFH $7.02
- HRMY $20.10
- Revenue Next Year
- DFH $2.12
- HRMY $18.01
- P/E Ratio
- DFH $6.65
- HRMY $12.17
- Revenue Growth
- DFH 21.19
- HRMY 20.62
- 52 Week Low
- DFH $19.65
- HRMY $26.47
- 52 Week High
- DFH $39.15
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- DFH 49.92
- HRMY 36.85
- Support Level
- DFH $21.95
- HRMY $32.39
- Resistance Level
- DFH $23.76
- HRMY $33.42
- Average True Range (ATR)
- DFH 1.13
- HRMY 1.06
- MACD
- DFH 0.02
- HRMY -0.47
- Stochastic Oscillator
- DFH 42.31
- HRMY 6.91
About DFH Dream Finders Homes Inc.
Dream Finders Homes Inc is engaged in the home building business. The company's primary focus is on constructing and selling single-family homes across entry-level, first-time move-up, second-time move-up, and active adult markets. Its homebuilding operations are organized into four reportable segments: Southeast, Mid-Atlantic, Midwest, and Financial Services. It generates the majority of its revenue from the Midwest segment.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.